SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-3.32%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$306M
AUM Growth
+$306M
(-2%)
Cap. Flow
+$5.38M
Cap. Flow
% of AUM
1.76%
Top 10 Holdings %
Top 10 Hldgs %
51.08%
Holding
39
New
6
Increased
12
Reduced
17
Closed
1
Top Buys
| 1 |
Merck
MRK
|
$16M |
| 2 |
Thermo Fisher Scientific
TMO
|
$10.3M |
| 3 |
Labcorp
LH
|
$5.11M |
| 4 |
Avantor
AVTR
|
$5.02M |
| 5 |
DexCom
DXCM
|
$4.36M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$16.3M |
| 2 |
Edwards Lifesciences
EW
|
$6.34M |
| 3 |
Tenet Healthcare
THC
|
$5.37M |
| 4 |
Amgen
AMGN
|
$4.19M |
| 5 |
Elevance Health
ELV
|
$3.89M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$141B
| $22.3M | 7.29% |
920,000
-5,000
| -0.5% | -$121K |
|
2
Medtronic
MDT
$119B
| $19.5M | 6.38% |
224,000
+19,000
| +9% | +$1.66M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $18.8M | 6.14% |
406,000
-29,000
| -7% | -$1.34M |
|
4
Becton Dickinson
BDX
$55.3B
| $16.9M | 5.52% |
98,000
+16,000
| +20% | +$2.76M |
|
|
5
Merck
MRK
$210B
| $16M | 5.23% |
+202,000
| New | +$16M |
|
6
Gilead Sciences
GILD
$140B
| $14.1M | 4.6% |
127,000
-13,000
| -9% | -$1.44M |
|
7
Incyte
INCY
$16.5B
| $13.9M | 4.54% |
204,000
+45,000
| +28% | +$3.06M |
|
|
8
Amgen
AMGN
$155B
| $12.3M | 4.02% |
44,000
-15,000
| -25% | -$4.19M |
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $11.3M | 3.69% |
285,842
| – | – |
|
10
CVS Health
CVS
$92.8B
| $11.2M | 3.68% |
163,000
-39,000
| -19% | -$2.69M |
|
11
Cardinal Health
CAH
$35.5B
| $11.1M | 3.62% |
66,000
-22,000
| -25% | -$3.7M |
|
|
12
Thermo Fisher Scientific
TMO
$186B
| $10.3M | 3.38% |
+25,500
| New | +$10.3M |
|
13
Centene
CNC
$14.3B
| $8.25M | 2.7% |
152,000
-25,000
| -14% | -$1.36M |
|
14
Baxter International
BAX
$12.7B
| $8.12M | 2.65% |
268,007
+20,357
| +8% | +$616K |
|
15
Zimmer Biomet
ZBH
$21B
| $8.08M | 2.64% |
88,631
-25,000
| -22% | -$2.28M |
|
16
Bruker
BRKR
$5.16B
| $8.07M | 2.64% |
195,970
-16,000
| -8% | -$659K |
|
|
17
Elevance Health
ELV
$71.8B
| $7.3M | 2.39% |
18,779
-10,000
| -35% | -$3.89M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.73M | 2.2% |
122,348
-15,000
| -11% | -$825K |
|
19
Biogen
BIIB
$19.4B
| $6.36M | 2.08% |
50,639
+32,000
| +172% | +$4.02M |
|
20
Humana
HUM
$36.5B
| $5.75M | 1.88% |
23,500
-1,500
| -6% | -$367K |
|
21
Qiagen
QGEN
$10.1B
| $5.62M | 1.84% |
117,000
-70,000
| -37% | -$3.36M |
|
22
GE HealthCare
GEHC
$33.7B
| $5.48M | 1.79% |
74,000
+12,000
| +19% | +$889K |
|
|
23
Labcorp
LH
$23.1B
| $5.11M | 1.67% |
+19,484
| New | +$5.11M |
|
|
24
Avantor
AVTR
$9.18B
| $5.02M | 1.64% |
+372,638
| New | +$5.02M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $4.51M | 1.47% |
92,250
| – | – |
|